[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hims & Hers Health Inc (HIMS)

Hims & Hers Health Inc (HIMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Hims & Hers Prepares to Explain an Eighty Percent Profit Decline Nobody Quite Understands Yet

Hims & Hers Health (HIMS) reports first-quarter 2026 earnings after market close on May 11, with Wall Street bracing for a dramatic profitability slowdown despite continued revenue growth. The telehealth platform faces a critical test: can management explain why earnings are expected to plunge 80% year-over-year while the business continues expanding, or will margin pressures prove more structural than investors hoped? With shares trading at $28.27 and analyst sentiment recently improving, the report will determine whether the recent rally can hold or if the profitability concerns trigger a broader reassessment.

Hims & Hers Health operates a direct-to-consumer telehealth platform offering personalized treatments for conditions including...

Fundamentals

See More
  • Market Capitalization, $K 6,443,836
  • Shares Outstanding, K 227,939
  • Annual Sales, $ 2,348 M
  • Annual Income, $ 128,370 K
  • EBIT $ 106 M
  • EBITDA $ 163 M
  • 60-Month Beta 2.43
  • Price/Sales 2.49
  • Price/Cash Flow 30.65
  • Price/Book 10.78

Options Overview Details

View History
  • Implied Volatility 104.24% (+6.72%)
  • Historical Volatility 91.24%
  • IV Percentile 78%
  • IV Rank 66.13%
  • IV High 127.22% on 10/16/25
  • IV Low 59.38% on 12/31/25
  • Expected Move (DTE 5) 3.84 (13.59%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 223,985
  • Volume Avg (30-Day) 203,912
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 1,155,540
  • Open Int (30-Day) 1,124,373
  • Expected Range 24.43 to 32.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.04
  • Number of Estimates 5
  • High Estimate $0.14
  • Low Estimate $-0.04
  • Prior Year $0.20
  • Growth Rate Est. (year over year) -80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.96 +49.10%
on 04/09/26
31.85 -11.25%
on 04/20/26
+8.88 (+45.80%)
since 04/08/26
3-Month
13.74 +105.75%
on 02/24/26
31.85 -11.25%
on 04/20/26
+5.25 (+22.81%)
since 02/06/26
52-Week
13.74 +105.75%
on 02/24/26
70.43 -59.86%
on 07/31/25
-23.13 (-45.00%)
since 05/08/25

Most Recent Stories

More News
Hims & Hers Health (HIMS) Reports Q1: Everything You Need To Know Ahead Of Earnings

Hims & Hers Health (HIMS) Reports Q1: Everything You Need To Know Ahead Of Earnings

HIMS : 28.27 (+10.21%)
Hims & Hers Prepares to Explain an Eighty Percent Profit Decline Nobody Quite Understands Yet

Barchart Research What to Expect from HIMS Earnings HIMS Generated May 8, 2026 Current Price $28.27 EPS Estimate $$0.04 Consensus Rating Hold Average Move 8.59% Hims & Hers Prepares to Explain an Eighty...

HIMS : 28.27 (+10.21%)
Hims & Hers Prepares to Explain an Eighty Percent Profit Decline Nobody Quite Understands Yet

Barchart Research What to Expect from HIMS Earnings HIMS Generated May 8, 2026 Current Price $28.27 EPS Estimate $$0.04 Consensus Rating Hold Average Move 8.59% Hims & Hers Prepares to Explain an Eighty...

HIMS : 28.27 (+10.21%)
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

HIMS : 28.27 (+10.21%)
NVO : 46.07 (+0.59%)
1 Stock Under $50 with Impressive Fundamentals and 2 We Ignore

1 Stock Under $50 with Impressive Fundamentals and 2 We Ignore

HLX : 9.66 (-1.73%)
HIMS : 28.27 (+10.21%)
IIIN : 26.97 (-0.55%)
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

HIMS : 28.27 (+10.21%)
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.

HIMS : 28.27 (+10.21%)
NVO : 46.07 (+0.59%)
LLY : 948.45 (-2.72%)
AMZN : 272.68 (+0.56%)
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise

HIMS : 28.27 (+10.21%)
Should You Buy HIMS Stock Following Friday's Rally?

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

HIMS : 28.27 (+10.21%)
Should You Buy the Dip in Eli Lilly Stock Today?

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

NVO : 46.07 (+0.59%)
HIMS : 28.27 (+10.21%)
LLY : 948.45 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Hims & Hers Health Inc. is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling medical care for numerous conditions related to mental health, sexual health, dermatology, primary care and more. Hims & Hers Health Inc., formerly known as Oaktree...

See More

Key Turning Points

3rd Resistance Point 32.52
2nd Resistance Point 30.52
1st Resistance Point 29.40
Last Price 28.27
1st Support Level 26.27
2nd Support Level 24.27
3rd Support Level 23.15

See More

52-Week High 70.43
Fibonacci 61.8% 48.77
Fibonacci 50% 42.08
Fibonacci 38.2% 35.40
Last Price 28.27
52-Week Low 13.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.